Efficacy and effectiveness of first-line oral medications in MS


REVIEWER: Mark S. Freedman, HBSc, MSc, MD, CSPQ, FANA, FAAN, FRCPC, Professor of Medicine (Neurology), University of Ottawa, Canada

NNT analysis
Natalizumab discontinuation studies
NeuroSens Survey on first-line orals

It takes 30 seconds

Recommend to a Colleague

Related Posts

Go back to home page